The role of 17β-estradiol (E2) in breast cancer development and tumor growth has traditionally been attributed exclusively to the activation of ERα. Although targeted inhibition of ERα is a successful approach for patients with ERα Implications: This is the first description of a role for the novel G protein-coupled estrogen receptor GPER in breast tumorigenesis and metastasis, demonstrating that it represents a new target in breast cancer diagnosis, prognosis and therapy.
Introduction
The steroid hormone 17β-estradiol (estrogen, E2) is the primary female sex hormone necessary for the development of secondary sexual characteristics in women. Specifically, E2 mediates the development of breast tissue during puberty and pregnancy by enhancing the proliferation of ductal epithelial cells. Similar to normal development, E2 also promotes breast cancer by augmenting proliferation, migration, and invasion of breast tumor cells, which has been demonstrated both in vitro and in vivo (1) . By inhibiting the activity of the classical estrogen receptor ERα, many cancer-promoting effects of E2 in cultured cells and mice are reduced; therefore, the actions of E2 in breast cancer have been attributed almost exclusively to ERα (2) . Clinically, drugs that block the production of estrogen or inhibit ERα, thereby inhibiting E2 signaling, increase long-term survival in patients with breast cancer (3) .
One of the most commonly prescribed adjuvant treatments for breast cancer is tamoxifen, a selective estrogen receptor modulator (SERM) that acts as an antagonist for ERα in the breast, inhibiting tumor growth. Treatment with tamoxifen for 5 years following surgery decreases mortality from breast cancer by approximately 30% (3), although the incidence of endometrial cancer increases by 2-4-fold (4) . However, only patients with ERα + tumors are eligible for treatment, and many ERα cancer.
G protein-coupled estrogen receptor (GPER, formerly GPR30) is a novel estrogen receptor with multiple functions in diverse tissues (8) (9) (10) (11) (12) , whose role in breast carcinogenesis has yet to be directly determined (13, 14) . E2 stimulation of cells expressing GPER but lacking ERα activates the MAPK and PI3K cascades, among other pathways, increasing proliferation of many breast cancer cell lines, suggesting GPER may play a role in one or more events of breast carcinogenesis (15) (16) (17) and particularly triple negative breast cancer (18, 19) . A small number of retrospective studies has examined the relationship between GPER expression in breast tumor samples and clinical outcome or its correlates. A study of 361 breast cancer patients found GPER expression associated with increased primary tumor size and the prevalence of distant metastasis (20) . Another investigation demonstrated an increased recurrence rate in GPER + invasive ductal breast cancers (21) . More recently, a study of invasive breast cancer samples demonstrated GPER expression is an independent prognostic factor for decreased disease-free survival in patients treated exclusively with tamoxifen (22) , with its cellular localization potentially playing a critical role (18) . While these studies suggest a role for GPER in breast cancer, to this point no direct experimental evidence demonstrates a functional role for GPER in the initiation and/or progression of breast cancer.
In this study, we investigated the contribution of GPER to breast carcinogenesis by introducing a GPER null mutation (GPER KO) (23, 24) Using the PyMT model, we demonstrate that the presence of GPER promotes growth and metastasis of late stage mammary tumors in PyMT mice, although we observed no difference in tumor latency between GPER WT PyMT (WT/PyMT) and GPER KO PyMT (KO/PyMT) mice. Further, early development of hyperplasia was not affected by GPER data demonstrate that silencing GPER decreases tumor size and the number of distant metastases, suggesting that pharmacological inhibition of GPER may represent a novel approach to reduce morbidity and mortality from breast cancer. 
Ovariectomy.
Ovariectomy was performed at 3 weeks of age. PyMT mice were anesthetized with isofluorane. A small incision was made through the skin on the dorsal midline just cranial to the hipbones. Bilateral incisions were made through the underlying muscle lateral to the spine and each ovary was removed. The muscle incisions were closed using polydioxanone synthetic absorbable sutures (PDS* Plus, Ethicon) and the skin incision was closed with 9 mm stainless steel tissue clips (ez CLIPS, Stoelting).
Tamoxifen treatment. When PyMT mice were 4-weeks-old, a 60-day release pellet containing tamoxifen (5 mg/pellet, Innovative Research of America) was subcutaneously implanted on the left dorsal side of the mouse just below the rib cage. Tumors were resected at 12 weeks of age and weighed as a measurement of tumor size.
Relative quantitation of PyMT gene expression. Mammary tumors from 13-14-week-old intact or ovariectomized PyMT mice and 10-week-old WT/PyMT and KO/PyMT were removed and homogenized in Trizol (Sigma-Aldrich) using a Polytron tissue homogenizer.
RNA isolation was performed in Trizol using phenol-chloroform extraction according to the manufacturers instructions. cDNA was created via reverse transcription of 1 μg RNA with the iScript cDNA synthesis kit (BioRad) using the GeneAmp PCR system 9700 (Applied Biosystems, Inc.) according to manufacturers directions. Quantification of PyMT mRNA relative to cytokeratin 18 mRNA was performed using Fast SYBR Green Immunostaining analysis. For immunostaining, 5 μm sections were deparaffinized, rehydrated, permeabilized in PBS containing 0.01% Triton X-100, and blocked in 3% normal goat serum (NGS) diluted in PBS plus 0.1% Tween-20 (PBS-T).
To evaluate cellular proliferation rate, microwave antigen retrieval was performed in 0.1 M sodium citrate (pH 6). Sections were incubated overnight in a 1:100 dilution of the antiphospho-histone H3 (P-histone H3, phospho Ser10, EMD Millipore) followed by detection with an anti-rabbit IgG antibody conjugated to Alexa 488 (Molecular Probes). Coverslips were mounted with Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories). One random field from 3 sections was imaged with a Zeiss 200M Axiovert microscope using MetaMorph® software. In a blinded manner, the number of Phistone H3-positive cells was determined and normalized to the total number of cells per field. Apoptosis was evaluated in the same manner, except the primary antibody was directed against cleaved caspase-3 (Asp 175, Cell Signaling).
To detect ERα, microwave antigen retrieval was performed in TET buffer (10mM Tris, 1mM EDTA, 0.05% Tween-20; pH 9) and endogenous peroxide activity was quenched in 3% H 2 Lung metastasis. Three 5 μm sections separated by 100 μm were prepared from the lungs of 12-13-week-old animals. Sections were deparaffinized, rehydrated, and stained with H&E.
Metastatic tumor foci present in the lung parenchyma are defined as a tightly clustered group of 10 or more hematoxylin-positive cells that excludes eosin-stained stroma. Total metastatic foci were counted in the three lung sections to determine the extent of metastasis. The counting was blinded to the investigator with respect to the genotype.
Whole Mount. Number 4 abdominal mammary glands from 7-week-old PyMT mice were fixed in 4% PFA on stretched skin overnight at room temperature. The glands were removed from the skin, incubated overnight in 100% acetone to remove the fat, washed in deionized water, and stained with carmine (Sigma-Aldrich) overnight as described (http://mammary.nih.gov).
After staining, the glands were washed in deionized water and dehydrated in ethanol before Additionally, as ovariectomy was more effective than tamoxifen at decreasing tumor size, ERα may not be the only estrogen receptor regulating tumor growth. We also concluded that, because of its E2 responsiveness, this model would be appropriate for examining the role of GPER in mammary tumorigenesis.
GPER deficiency does not affect tumor initiation or early tumor proliferation. GPER WT, HET,
and KO mice on a PyMT background (WT/PyMT, HET/PyMT, KO/PyMT, respectively) were generated. Tumors in both WT/PyMT and KO/PyMT mice were palpable between 7 and 8 weeks of age, suggesting no difference in tumor latency. To assess differences in early tumor development, whole mounts of the number 4 abdominal mammary glands from 7-week-old WT/PyMT and KO/PyMT mice were stained with carmine to determine the extent of hyperplasia as follows. In Image J, a grid was overlaid on the whole mount images and each box was evaluated for the presence of hyperplasia and epithelium (Figure 2A 
Discussion
Several reports have demonstrated that multiple cancer cell lines proliferate in response to the GPER-selective agonist G-1 (36-38) and that E2-dependent proliferation can be reduced upon silencing GPER expression or inhibiting GPER activity (16, (39) (40) (41) . While these data suggest GPER may promote breast tumor growth, its importance in breast cancer initiation, growth and progression has remained unexplored. This report is therefore the first to describe a role for GPER in both tumor progression and metastasis using an in vivo model of breast carcinogenesis.
In this study, WT/PyMT and KO/PyMT mice were compared to determine the effects of 
dependent invasion through a recombinant basement membrane due to increased MMP-9 expression and activation (52), one of the first steps of metastasis. Furthermore, in vitro migration is enhanced through GPER activation in tumor cells as well as cells in the microenvironment, specifically fibroblasts, through induction of CTGF expression. Increased CTGF expression is critical for stimulating cell migration (45) . While these mechanisms have been described for GPER mediating tumor cell "escape" from their local environment, the role of GPER at the site of distant metastasis has not been examined. Tumor cell metastasis to distant sites cannot be successful unless the invasive tumor cells can survive and proliferate in the new environment. Therefore, it is important to determine if GPER augments metastasis through enhancing the ability of cells to escape the tumor microenvironment, supporting the ability of tumor cells to survive and grow in a novel environment, or both.
Understanding the mechanisms of GPER-mediated metastasis will enhance our ability to effectively target GPER to inhibit metastasis.
While these in vitro data have given insight into the possible role(s) of GPER in breast cancer aggressiveness, it is important to recognize that clinical studies have also demonstrated a correlation between GPER expression and tumor size, metastasis, and recurrence. In one retrospective analysis by Filardo and colleagues, high GPER expression in breast tumors correlated with larger tumor size and increased distant metastasis, consistent with results of this study. Furthermore, it has been proposed that GPER plays a role in tamoxifen resistance and recurrence following tamoxifen therapy. While tamoxifen is a selective estrogen receptor modulator (SERM) that inhibits ERα in the breast, it ubiquitously activates GPER, possibly contributing to tamoxifen resistance and the development of tamoxifen-associated uterine 
cancer (53) . In a retrospective study, Ignatov and colleagues demonstrated that in patients treated with tamoxifen as a monotherapy, high GPER expression correlated with subsequent tamoxifen resistance and decreased relapse-free survival (22) . Therefore, administering a GPER-selective antagonist following or in combination with tamoxifen could represent an approach to inhibit resistance and improve the efficacy of tamoxifen and other SERMs (40, 53) . Furthermore, tamoxifen is only effective in patients with ERα-positive tumors, leaving ~30% of breast cancer patients with fewer treatment options (32). However, 60% of patients with ERα-negative tumors express GPER (20, 22) that may be enhancing tumor growth and metastasis, providing a novel therapeutic target in these patients. Given the possible roles of GPER in tamoxifen-resistant and ERα-negative tumors, GPER is an appealing target to reduce tumor growth and metastasis, especially in premenopausal women who are not candidates for aromatase inhibitor therapy.
In conclusion, this is the first in vivo study to demonstrate a role for GPER in the progression of breast cancer, identifying a novel target for hormone therapy in breast cancer. As GPER is expressed in 60% of ERα-negative tumors, targeting GPER could increase patient survival in women with the more aggressive ERα-negative tumors. GPER expression is also associated with increased recurrence after adjuvant treatment with tamoxifen as a monotherapy (20, 22) , and, therefore, may be an effective therapeutic target in combination with tamoxifen or other SERMs. Finally, as GPER-selective small molecule inhibitors (G15 and G36) (54, 55) (n = 6) mice were stained with carmine to visualize hyperplasia. Using Image J software, a grid was overlaid on the image, and each box was analyzed for the presence of hyperplasia and normal epithelium. Hyperplasia was analyzed in the total gland and distal to the lymph node (dashed circle). B) Quantification of total gland hyperplasia. The number of boxes containing hyperplasia was normalized to the number of boxes containing total epithelium, which is defined as hyperplastic and normal epithelium. C) Quantification of hyperplasia distal to the lymph node performed in the same manner as in B. D) Number 2/3 mammary glands from 7-week-old WT/PyMT (n = 6) and KO/PyMT (n = 3) mice were stained with antiphospho histone-H3 (P-H3) antibody to determine proliferation rate. Statistical analysis was done using two-tailed Student's t-test with a p-value threshold of 0.05. 
